 OPN-019 will combine the Companys proprietary nasal Exhalation Delivery System EDS technology with an antiseptic that has been recently shown in vitro to kill the virus that causes COVID-19. Because components of the drug-device combination product candidate, including both the active drug and delivery device, are currently commercially available in the U.S., the Company expects to be able to rapidly progress to a meeting with FDA to discuss an IND and then onward to clinical trials. 